1. Market Research
  2. > Pharmaceutical Market Trends
Neurodegenerative Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Neurodegenerative Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • July 2021
  • 139 pages
  • ID: 6106013
  • Format: PDF
  • Mordor Intelligence LLP
Up to $750 off Until Sep 30th 2021


Table of Contents

Search Inside

The Neurodegenerative Disease market was valued at approximately USD 39.24 billion in 2020 and is expected to witness a revenue of USD 44.90 billion in 2026, with a CAGR of 2.30% over the forecast period.

The COVID-19 impact on the Neurodegenerative Disease market is expected to be significant as the pandemic has impacted the workflows of clinical trials, research, and development activities, and pipeline products, leading to relatively slow growth during the pandemic, despite the presence of robust late-stage product pipeline. For instance, recently, in 2020, Biogen has delayed Alzheimer’s drug filing to FDA, while citing the complexity of data analysis, and the impact of COVID-19 on its research and development resources. However, in January 2021, Biogen and Eisai Co., Ltd. announced that the U.S. Food and Drug Administration has extended the review period by 3 months for the Biologics License Application for aducanumab, an investigational treatment for Alzheimer’s disease. Thus, owing to the aforementioned factors, the studied market is expected to witness a short-term decline in the studied market growth during the COVID-19 pandemic.

The major factors for the growth of the neurodegenerative disease market include the rising prevalence of neurological disorders, increasing public awareness, and a strong product pipeline for neurodegenerative disease treatment. With increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer’s and related dementia, and this number is further expected to reach 152 million by 2050. Additionally, elderly people are a rapidly growing proportion of the world’s population. Also, as per the National Multiple Sclerosis Society, nearly one million people are living with Multiple Sclerosis in the United States in 2019. According to World Population Prospects, 2019 statistics, by 2050, one in six people in the world will be over age 65 and at present it is one in 11. By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The number of persons aged 80 years or over is projected to triple, from 143 million in 2019 to 426 million in 2050 globally.? As the geriatric population are more prone to the neurodegenerative diseases, the growing elderly population globally is expected to drive th growth o studies market. Furthermore, the growing awareness among the population about neurodegenerative diseases and its treatment options is expected to drive the market growth. For instance, American Parkinson Disease Association, in 2020, launched a new public service announcement that encourages viewers to look closer at Parkinson’s disease. This program was featured in the national television and social media. Thus, the aforementioned factors are expected to aid in the growth of the studied market over the forecast period. However, stringent regulatory guidelines and patent expiry of neurodegenerative disease treatment products are the major factors that are anticipated to hinder the market growth.

Key Market Trends
Alzheimer’s Disease Segment is Expected to Witness Significant Growth Over the Forecast Period

Alzheimer’s disease (AD) is a progressive disorder that causes brain cells to waste away (degenerate) and die. Alzheimer’s disease is the most common cause of dementia, which is a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently. The prevalence and mortality due to the disease are increasing globally, especially in more developed parts of the world. According to the 2021 Alzheimer’s Disease Facts and Figures report released by Alzheimer’s Association, it was estimated that in the United States around 6.2 million people of age 65 and older are living with Alzheimer’s dementia in 2021. 1 in 9 people aged 65 and older has Alzheimer’s dementia and about two-thirds of Americans with Alzheimer’s are women. The high incidence of Alzheimer’s disease is expected to have a positive impact on the studied segment growth. Additionally, the growing research and development activities and new product launches also aid in the growth of the segment growth. For instance, in January 2021, Eli Lilly and Company’s revealed the results of a study of Donanemab, an investigational antibody that targets a modified form of beta-amyloid called N3pG, which showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer’s disease compared to placebo in results from its Phase 2 TRAILBLAZER-ALZ study. Thus, owing to the aforementioned factors, the Alzheimer’s disease segment is expected to witness significant growth in the coming years.

North America Holds the Major Share in the Studied Market and is Expected to Dominate the Market Over the Forecast Period

North America is the most significant region in the Neurodegenerative Disease market. According to Parkinson’s Foundation, nearly one million were expected to be living with Parkinson’s disease in the United States in 2020, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy, and Lou Gehrig’s disease and is expected to rise to 1.2 million by 2030. Approximately 60,000 Americans were diagnosed with Parkinson’s disease each year, with a collective direct and indirect cost of Parkinson’s, including treatment, social security payments, and lost income is estimated to be nearly USD 52 billion per year in the United States alone and more than 10 million people worldwide were living with PD. Also, as per the January 2020 report of the Public Health Agency of Canada, it was found that more than 432,000 Canadians aged 65 and older are living with diagnosed dementia, including Alzheimer’s disease. Thus, the growing burden of neurodegenerative disease in the region is expected to drive the studied market growth.

Moreover, North American is expected to dominate the market due to the presence of a large number of drug manufacturers and the advancing paradigm of care for neurodegenerative disease patients that is supporting the growth in this region. For instance, in February 2020, Merck & Co., Inc. received approval from the United States Food and Drug Administration (FDA) for an update to the prescribing information for BELSOMRA (suvorexant) C-IV to include findings on its use for the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease. The advancements in novel technology for the treatment of neurodegenerative diseases and strong product pipeline for wasting syndrome has also helped in the growth of the neurodegenerative disease market in the region. Thus, owing to the aforementioned factors, the studied market is anticipated to propel significantly in North America over the forecast period.

Competitive Landscape
The market studied is moderately competitive. Some of the major market players are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical, Novartis AG, and UCB SA. The major players are involved in strategic alliances such as mergers and acquisitions, partnerships and collaborations, along with investment in research and development activities and new product launches to withstand the global competitive rivalry. For instance, in March 2021, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) and Eisai Co., Ltd. entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glial cells.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Single-use Bioreactors Market by Product, Molecule, Cell type, Application, End User - Global Forecast to 2026

  • $ 4950
  • August 2021
  • 350 pages

The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. Increasing adoption of SUBs among small ...

  • World
  • Europe
  • Pharmaceutical
  • Biotechnology
  • Industry analysis
  • Pharmaceutical Exports
  • Pharmaceutical Production


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on